89Bio IncNASDAQ ETNB Stock Report

89bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company is headquartered in San Francisco, California and currently employs 45 full-time employees. The company went IPO on 2019-11-11. The firm's lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). NASH is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma (HCC) and death. The firm is evaluating the potential opportunity for pegozafermin in these fibrosis stage F4 patients. SHTG is a condition identified by severely elevated levels of triglycerides. The firm has initiated its Phase II trial (ENTRIGUE) in SHTG patients.